Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study

Benjamin Waschki, Peter Alter, Tanja Zeller, Christina Magnussen, Johannes T. Neumann, Raphael Twerenbold, Christoph Sinning, Christian Herr, Kathrin Kahnert, Sebastian Fähndrich, Stefan Blankenberg, Klaus F. Rabe, Tobias Welte, Rudolf A. Jörres, Claus F. Vogelmeier, Robert Bals, Henrik Watz on behalf of the German COSYCONET Cohort
European Respiratory Journal 2019; DOI: 10.1183/13993003.01314-2019
Benjamin Waschki
1Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
2LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Grosshansdorf, Germany
3German Center for Lung Research (DZL)
4German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin Waschki
  • For correspondence: b.waschki@uke.de
Peter Alter
3German Center for Lung Research (DZL)
5Department of Medicine, Pulmonary and Critical Care Medicine, Philipps-University of Marburg (UMR), Marburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter Alter
Tanja Zeller
1Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
4German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Magnussen
1Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
4German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes T. Neumann
1Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphael Twerenbold
1Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Sinning
1Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Herr
6Department of Internal Medicine V - Pulmonology, Allergology, Critical Care Care Medicine, Saarland University Hospital, Homburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathrin Kahnert
3German Center for Lung Research (DZL)
7Department of Internal Medicine V, University of Munich (LMU), Comprehensive Pneumology Center, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Fähndrich
8Department of Pneumology, University Medical Center Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Blankenberg
1Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
4German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus F. Rabe
2LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Grosshansdorf, Germany
3German Center for Lung Research (DZL)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Welte
3German Center for Lung Research (DZL)
9Department of Respiratory Medicine, Hannover Medical School, Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rudolf A. Jörres
3German Center for Lung Research (DZL)
10Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, Ludwig Maximilians University (LMU) Munich, Comprehensive Pneumology Center Munich (CPC-M), Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claus F. Vogelmeier
3German Center for Lung Research (DZL)
5Department of Medicine, Pulmonary and Critical Care Medicine, Philipps-University of Marburg (UMR), Marburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Bals
6Department of Internal Medicine V - Pulmonology, Allergology, Critical Care Care Medicine, Saarland University Hospital, Homburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert Bals
Henrik Watz
3German Center for Lung Research (DZL)
11Pulmonary Research Institute at LungenClinic Grosshansdorf, ARCN, Grosshansdorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of death with a considerable part of the population dying from cardiovascular diseases. High-sensitivity troponin I (hs-TnI) might help to better identify COPD patients at high risk of mortality. We aimed to study the predictive value of hs-TnI for all-cause mortality beyond established COPD assessments, and after consideration of relevant cardiovascular risk factors and prevalent cardiovascular diseases, in a broad population with stable COPD.

Circulating hs-TnI concentrations together with a wide range of respiratory and cardiovascular markers were evaluated in 2085 patients with stable COPD across all severity stages enrolled in the multi-center COSYCONET cohort study. The primary outcome was all-cause mortality over 3 years of follow-up.

Hs-TnI was detectable in 2020 (96.9%) patients. The median hs-TnI concentration was 3.8 ng·L−1 (IQR, 2.5‒6.6 ng·L−1) with levels above the 99th percentile reference limit of 27 ng·L−1 observed in 1.8% patients. In Cox regression analyses including adjustments for airflow limitation, dyspnea grade, exercise capacity, and history of severe exacerbations, as well as traditional cardiovascular risk factors, estimated glomerular filtration rate, ankle-brachial index, N-terminal pro-brain natriuretic peptides, and prevalent cardiovascular diseases, hs-TnI was a significant predictor for all-cause mortality, both as a continuous variable (HR for log hs-TnI, 1.28 [95%CI, 1.01‒1.62]) and categorised according to the cut-off of 6 ng·L−1 (HR, 1.63 [95%CI, 1.10‒2.42]).

In patients with stable COPD, hs-TnI is a strong predictor of all-cause mortality beyond established COPD mortality predictors, and independent of a broad range of cardiovascular risk factors and prevalent cardiovascular diseases. Hs-TnI concentrations well-below the upper reference limit provide further prognostic value for all patients with COPD when added to established risk assessments.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Waschki has nothing to disclose.

Conflict of interest: Dr. Alter reports grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), grants from AstraZeneca GmbH, grants and non-financial support from Bayer Schering Pharma AG, grants, personal fees and non-financial support from Boehringer Ingelheim Pharma GmbH & Co. KG, grants and non-financial support from Chiesi GmbH, grants from GlaxoSmithKline, grants from Grifols Deutschland GmbH, grants from MSD Sharp & Dohme GmbH, grants and personal fees from Mundipharma GmbH, grants, personal fees and non-financial support from Novartis Deutschland GmbH, grants from Pfizer Pharma GmbH, grants from Takeda Pharma Vertrieb GmbH & Co. KG, outside the submitted work.Dr. Alter reports grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), grants from AstraZeneca GmbH, grants and non-financial support from Bayer Schering Pharma AG, grants, personal fees and non-financial support from Boehringer Ingelheim Pharma GmbH & Co. KG, grants and non-financial support from Chiesi GmbH, grants from GlaxoSmithKline, grants from Grifols Deutschland GmbH, grants from MSD Sharp & Dohme GmbH, grants and personal fees from Mundipharma GmbH, grants, personal fees and non-financial support from Novartis Deutschland GmbH, grants from Pfizer Pharma GmbH, grants from Takeda Pharma Vertrieb GmbH & Co. KG, outside the submitted work.

Conflict of interest: Dr. Zeller has nothing to disclose.

Conflict of interest: Dr. Magnussen has nothing to disclose.

Conflict of interest: Dr. Neumann reports personal fees from Abbott Diagnostics, personal fees from Siemens, outside the submitted work.

Conflict of interest: Dr. Twerenbold reports grants from Swiss National Science Foundation (Grant No P300PB_167803), grants from Swiss Heart Foundation, grants from Swiss Society of Cardiology, grants from Cardiovascular Research Foundation Basel, personal fees from Abbott Diagnostics, personal fees from Amgen, personal fees from Roche Diagnostics, personal fees from Siemens, personal fees from Singulex, personal fees from BRAHMS, outside the submitted work.

Conflict of interest: Dr. Sinning has nothing to disclose.

Conflict of interest: Dr. Herr has nothing to disclose.

Conflict of interest: Dr. Kahnert has nothing to disclose

Conflict of interest: Dr. Fähndrich has nothing to disclose.

Conflict of interest: Dr. Blankenberg reports personal fees from Abbott Diagnostics, personal fees from Siemens, personal fees from Thermo Fisher, personal fees from Singulex outside the submitted work.

Conflict of interest: Dr. Rabe has nothing to disclose.

Conflict of interest: Dr. Welte reports personal fees from AstraZeneca, Boehringer, Berlin Chemie, Chiesi, GSK, Novartis, grants from AstraZeneca, Novartis, outside the submitted work.

Conflict of interest: Dr. Jörres has nothing to disclose.

Conflict of interest: Dr. Vogelmeier reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from CSL Behring, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants and personal fees from Grifols, personal fees from Menarini, personal fees from Mundipharma, grants and personal fees from Novartis, personal fees from Teva, personal fees from Cipla, grants from Bayer-Schering, grants from MSD, grants from Pfizer, outside the submitted work.

Conflict of interest: Dr. Bals reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from GlaxoSmithKline, personal fees from Grifols, grants and personal fees from Novartis, personal fees from CSL Behring, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), grants from Sander Stiftung, grants from Schwiete Stiftung, grants from Krebshilfe, grants from Mukoviszidose eV, outside the submitted work.

Conflict of interest: Dr. Watz reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from GlaxoSmithKline, personal fees from BerlinChemie, personal fees from Chiesi, personal fees from Novartis , personal fees from Roche, outside the submitted work.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received July 3, 2019.
  • Accepted November 11, 2019.
  • Copyright ©ERS 2019
PreviousNext
Back to top
View this article with LENS
Vol 62 Issue 3 Table of Contents
European Respiratory Journal: 62 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study
Benjamin Waschki, Peter Alter, Tanja Zeller, Christina Magnussen, Johannes T. Neumann, Raphael Twerenbold, Christoph Sinning, Christian Herr, Kathrin Kahnert, Sebastian Fähndrich, Stefan Blankenberg, Klaus F. Rabe, Tobias Welte, Rudolf A. Jörres, Claus F. Vogelmeier, Robert Bals, Henrik Watz
European Respiratory Journal Jan 2019, 1901314; DOI: 10.1183/13993003.01314-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study
Benjamin Waschki, Peter Alter, Tanja Zeller, Christina Magnussen, Johannes T. Neumann, Raphael Twerenbold, Christoph Sinning, Christian Herr, Kathrin Kahnert, Sebastian Fähndrich, Stefan Blankenberg, Klaus F. Rabe, Tobias Welte, Rudolf A. Jörres, Claus F. Vogelmeier, Robert Bals, Henrik Watz
European Respiratory Journal Jan 2019, 1901314; DOI: 10.1183/13993003.01314-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Prior CV disease and mortality COPD pneumonia patients
  • Factors associated with FEV1 decline in CF
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society